ARCA biopharma Announces Management Transitions
December 01 2014 - 5:00PM
Business Wire
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
developing genetically-targeted therapies for cardiovascular
diseases, today announced three management team transitions.
Patrick Wheeler, ARCA’s Chief Financial Officer, has notified
ARCA of his intent to leave the company in order to pursue other
career opportunities after having served ARCA for 9 years. He will
remain with the company through December 31, 2014 to assist in the
transition of his responsibilities. Mr. Wheeler joined the company
in 2006 and has held financial and senior management positions of
increasing responsibility throughout his tenure.
Brian Selby has been promoted to Vice President, Finance and
Chief Accounting Officer. He will report to the CEO and be
responsible for ARCA’s internal and external financial reporting,
including compliance with the rules and regulations of the U.S.
Securities and Exchange Commission, and corporate financing
activities. Mr. Selby has been the company’s Controller for 7 years
and has extensive experience in corporate accounting and finance.
Prior to joining ARCA, he worked at several public companies,
including Controller for Myogen, Inc. and Controller for Genomica
Corporation.
Thomas Keuer has been promoted to Chief Operating Officer. He
will report to the CEO and be responsible for pharmaceutical
operations, human resources, facilities, and information
technology. Mr. Keuer has been the Company’s Executive Vice
President, Pharmaceutical Operations for the past 8 years. Prior to
joining ARCA, he served in a number of senior leadership positions
in the biopharmaceutical industry including SVP of Operations for
Insmed, Inc., VP of Engineering for Baxter Healthcare, and VP of
Operations for Somatogen, Inc.
“Pat has been a tremendous asset to the Company over the past 9
years, helping shape our strategy, financing and development,” said
Michael R. Bristow, President and CEO for ARCA. “We are grateful
for his service and contributions and wish him well in all his
future endeavors. I am very pleased with the abilities of our
people with such longevity within the company to continue the
leadership of the organization. I look forward to continuing
working with Tom and Brian in their expanded roles. Their industry
and professional experience will be valuable as ARCA continues the
development of Gencaro as a potential treatment for atrial
fibrillation.”
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted
therapies for cardiovascular diseases. The Company's lead product
candidate, GencaroTM (bucindolol hydrochloride), is an
investigational, pharmacologically unique beta-blocker and mild
vasodilator being developed for atrial fibrillation. ARCA has
identified common genetic variations that it believes predict
individual patient response to Gencaro, giving it the potential to
be the first genetically-targeted atrial fibrillation prevention
treatment. ARCA has a collaboration with Medtronic, Inc. for
support of the GENETIC-AF trial. For more information, please visit
www.arcabiopharma.com.
Safe Harbor Statement
This press release contains "forward-looking
statements" for purposes of the safe harbor provided by the Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements regarding, the potential for
genetic variations to predict individual patient response to
Gencaro, Gencaro’s potential to treat atrial fibrillation, and the
potential for Gencaro to be the first genetically-targeted atrial
fibrillation prevention treatment. Such statements are based on
management's current expectations and involve risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, the
risks and uncertainties associated with: the Company's financial
resources and whether they will be sufficient to meet the Company's
business objectives and operational requirements; results of
earlier clinical trials may not be confirmed in future trials, the
protection and market exclusivity provided by the Company’s
intellectual property; risks related to the drug discovery and the
regulatory approval process; and, the impact of competitive
products and technological changes. These and other factors are
identified and described in more detail in ARCA’s filings with the
SEC, including without limitation the Company’s annual report on
Form 10-K for the year ended December 31, 2013, and subsequent
filings. The Company disclaims any intent or obligation to update
these forward-looking statements.
ARCA biopharma, Inc.Investor & Media
Contact:Derek Cole,
720-940-2163derek.cole@arcabiopharma.com
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Apr 2023 to Apr 2024